Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

Nirsevimab (Beyfortus) for Respiratory Syncytial Virus Prevention in Neonates and Infants

Details

Files
Project Status:
Complete
Project Line:
Health Technology Review
Project Sub Line:
Technology Review
Project Number:
HC0059-000

Nirsevimab (Beyfortus) is a humanized monoclonal antibody for intramuscular administration for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. Canada's Drug Agency conducted a review of the evidence and convened an implementation advice panel to prioritize the patient populations that were at high risk of severe RSV disease and most likely to benefit from nirsevimab.

Files

Nirsevimab (Beyfortus) for Respiratory Syncytial Virus Prevention in Neonates a… View PDF
Last Updated : July 26, 2023